Exploratory biomarker analysis from a phase III study of the PI3K inhibitor, copanlisib, in combination with rituximab in patients with indolent non-Hodgkin lymphoma, a retrospective study
PTEN presence, BCL2 mutations, and low or undetectable baseline IL-2 levels were associated with improved patient survival following treatment with C + R, supporting a potential role for these biomarkers in guiding treatment selection for patients with indolent non-Hodgkin lymphoma.
Authors
- Sara Bellinvia (ORCID: https://orcid.org/0000-0002-6311-3112)
- Anke Weispfenning
- Tine Descamps (ORCID: https://orcid.org/0000-0002-8874-2214)
- Barrett H. Childs (ORCID: https://orcid.org/0000-0001-9801-4619)
- Lidia Mongay Soler (ORCID: https://orcid.org/0000-0002-8588-1200)
- Teresa F. Lunt
- Pier Luigi Zinzani (ORCID: https://orcid.org/0000-0002-2112-2651)
- Rong Du (ORCID: https://orcid.org/0009-0004-9737-9359)
- David R. Bauer (ORCID: https://orcid.org/0009-0005-7490-3397)
- Shalini Chaturvedi
Institutions
- Bayer (United States) (US)
- Istituto di Ematologia di Bologna (IT)
- Bayer (China) (CN)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- University of Bologna (IT)
Publication Details
- Journal
- Clinical & Translational Oncology
- Published
- 2025-02-21
- DOI
- https://doi.org/10.1007/s12094-025-03869-2
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47
Funders
- Bayer
- Bayer Corporation